List of works - Robert J Kreitman

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo

scientific article

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies

scientific article

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

scientific article

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

scientific article

BL22 and lymphoid malignancies

scientific article published on January 2006

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

scientific article

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

scientific article published on 30 December 2011

Characterization of CD22 expression in acute lymphoblastic leukemia

scientific article published on March 2015

Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides

scientific article published on 9 October 2015

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

scientific article

Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome

scientific article

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model

scientific article

Evidence of canonical somatic hypermutation in hairy cell leukemia

scientific article

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

scientific article published on 10 February 2020

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

scientific article published on February 2005

Immunobiological treatments of hairy-cell leukaemia

scientific article

Immunoconjugates in the management of hairy cell leukemia

scientific article

Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies

scientific article

Immunotoxin therapy of hematologic malignancies

scientific article

Immunotoxin treatment of cancer

scientific article

Immunotoxins in the treatment of hematologic malignancies

scientific article published on October 2006

Immunotoxins in the treatment of refractory hairy cell leukemia

scientific article published on October 2006

Impact of telomere length on survival in classic and variant hairy cell leukemia

scientific article

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

scientific article

In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin

scientific article

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

scientific article published on 05 October 2021

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

scientific article published on August 2005

Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments

scientific article published on July 2002

PRAME expression in hairy cell leukemia

scientific article published on 4 March 2008

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

scientific article

Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia

scientific article

Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.

scientific article

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

scientific article

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

scientific article

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

scientific article

Recombinant immunotoxins for the treatment of haematological malignancies

scientific article published in July 2004

Recombinant immunotoxins for treating cancer

scientific article published on April 2004

Recombinant toxins for the treatment of cancer

scientific article

Removing a hair of doubt about BRAF targeting

scientific article

Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera

scientific article

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

scientific article

Soluble CD22 as a tumor marker for hairy cell leukemia

scientific article published on 2 July 2008

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

scientific article published on 8 November 2011

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

scientific article

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

scientific article

The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan

scientific article published on September 2011

Thrombotic microangiopathy with targeted cancer agents

scientific article

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates

scientific article

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

scientific article

Variables in the quantification of CD4 in normals and hairy cell leukemia patients ⬇️

scientific article published on January 1, 2011

List of works by Robert J Kreitman

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

BL22 and lymphoid malignancies

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

Characterization of CD22 expression in acute lymphoblastic leukemia

Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model

Evidence of canonical somatic hypermutation in hairy cell leukemia

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Immunobiological treatments of hairy-cell leukaemia

Immunoconjugates in the management of hairy cell leukemia

Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies

Immunotoxin therapy of hematologic malignancies

Immunotoxin treatment of cancer

Immunotoxins in the treatment of hematologic malignancies

Immunotoxins in the treatment of refractory hairy cell leukemia

Impact of telomere length on survival in classic and variant hairy cell leukemia

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments

PRAME expression in hairy cell leukemia

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia

Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Recombinant immunotoxins for the treatment of haematological malignancies

Recombinant immunotoxins for treating cancer

Recombinant toxins for the treatment of cancer

Removing a hair of doubt about BRAF targeting

Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Soluble CD22 as a tumor marker for hairy cell leukemia

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan

Thrombotic microangiopathy with targeted cancer agents

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

Variables in the quantification of CD4 in normals and hairy cell leukemia patients ⬇️